Futura Medical Preliminary Results for the year ended 31 December 2018

Sustained Progress made in 2018

Futura Medical plc (AIM: FUM), the pharmaceutical company developing a portfolio of innovative products for sexual health and pain, based on its proprietary, transdermal DermaSys® drug delivery technology is pleased to announce its preliminary results for the year ended 31 December 2018.

Highlights

Operational highlights

  • Following an extensive strategic review which was announced in September 2018, Futura has focused on maximising value in its development pipeline and product portfolio addressing two large market categories, sexual health and pain. The lead priorities are MED2005, its innovative topical treatment for erectile dysfunction (ED), and its pain portfolio including TPR100, a topical non-steroidal anti-inflammatory drug. Futura’s core objectives are to:
  1. complete the development of MED2005, currently in Phase 3 clinical trial, and
  2. further realise value from the pain portfolio.
  • In February 2018, Angela Hildreth joined Futura in the role of Finance Director, Chief Operating Officer and Board Director.

Read more

By Optimum

For more information about Optimum Strategic Communications, please get in touch

We'd love to hear from you...

GET IN TOUCH